ABSTRACT NUMBER: ESOC2026A447 EFFICACY AND SAFETY OF TAFOLECIMAB IN PATIENTS WITH CEREBROVASCULAR DISEASE AND HYPERCHOLESTEROLEMIA: A POST-HOC ANALYSIS OF POOLED DATA FROM THREE PHASE 3 TRIALS

Hua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo · 2026

Read ABSTRACT NUMBER: ESOC2026A447 EFFICACY AND SAFETY OF TAFOLECIMAB IN PATIENTS WITH CEREBROVASCULAR DISEASE AND HYPERCHOLESTEROLEMIA: A POST-HOC ANALYSIS OF POOLED DATA FROM THREE PHASE 3 TRIALS by Hua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145423.txt.

Description

Hua Shen and co-authors pool data from three phase 3 trials to test a cholesterol-lowering antibody in patients who have both blood-vessel disease in the brain and high cholesterol. Such patients face a high risk of another stroke or vascular event. The drug, tafolecimab, blocks a protein called PCSK9 and had already cut LDL cholesterol in broader patient groups.

The analysis covers 148 patients with cerebrovascular disease, 106 on the drug and forty-two on placebo, dosed every four weeks. At twelve weeks, LDL cholesterol had fallen by about sixty-two percent on the drug while rising slightly on placebo. Nearly all treated patients reached the target cholesterol level, versus a small share on placebo. Side effects occurred at similar rates in both groups, with none serious and tied to the drug.

Catalog record

CREATORHua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13145423

Browse the full library · About the Tower of Babel